Seoul National University Bundang Hospital — Biomedical Watch V2

Traitements5programmes

Essais2liés

Publications1liées

SourceDBlocale

Traitements

5

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Cilostazol / Ginko Leaf Dried Ext.This exploratory pilot study aims to evaluate the cognitive improvement effects of combination therapy with cilostazol (200 mg) and ginkgo biloba extract (160 mg) in elderly patients with type 2 diabetes mellitus. Both agents have demonstrated potential cognitive benefits through mechanisms such as enhanced cerebral blood flow, anti-inflammatory activity, and neuroprotection. Given the increased risk of cognitive decline and dementia in patients with type 2 diabetes, and the need for preventive strategies, this study will investigate whether the combination therapy can prevent or mitigate cognitive deterioration. Findings from this study may provide foundational data for the future development of therapeutic interventions targeting cognitive impairment in patients with diabetes.	Alzheimer	Phase 3	Neuroprotection + Immunomodulation	South Korea	À vérifier
Oxaliplatin, 5FU, leucovorinIn second line with advanced or recurrent biliary tract cancer refractory to first line gemcitabine plus cisplatin,efficacy of mFOLFOX/FOLFIRI vs mFOLFOX will be evaluated at randomized phase 2 trial.	Cancer	Phase 2	À vérifier	South Korea	À vérifier
Oxaliplatin, 5FU, leucovorin/Irinotecan , 5FU, leucovorin,In second line with advanced or recurrent biliary tract cancer refractory to first line gemcitabine plus cisplatin,efficacy of mFOLFOX/FOLFIRI vs mFOLFOX will be evaluated at randomized phase 2 trial.	Cancer	Phase 2	À vérifier	South Korea	À vérifier
Cilostazol / Ginko Leaf Dried Ext.This exploratory pilot study aims to evaluate the cognitive improvement effects of combination therapy with cilostazol (200 mg) and ginkgo biloba extract (160 mg) in elderly patients with type 2 diabetes mellitus. Both agents have demonstrated potential cognitive benefits through mechanisms such as enhanced cerebral blood flow, anti-inflammatory activity, and neuroprotection. Given the increased risk of cognitive decline and dementia in patients with type 2 diabetes, and the need for preventive strategies, this study will investigate whether the combination therapy can prevent or mitigate cognitive deterioration. Findings from this study may provide foundational data for the future development of therapeutic interventions targeting cognitive impairment in patients with diabetes.	Alzheimer	Phase 3	Neuroprotection + Immunomodulation	South Korea	À vérifier
Oxaliplatin, 5FU, leucovorinIn second line with advanced or recurrent biliary tract cancer refractory to first line gemcitabine plus cisplatin,efficacy of mFOLFOX/FOLFIRI vs mFOLFOX will be evaluated at randomized phase 2 trial.	Cancer	Phase 2	À vérifier	South Korea	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
Oxaliplatin, 5FU, leucovorin	Cancer	Phase 2	NCT07062536	mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line	RECRUITING
Cilostazol / Ginko Leaf Dried Ext.	Alzheimer	Phase 3	NCT06989697	Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes	RECRUITING

Publications

1

Molécule	Indication / population	Titre	Journal	Date
Oxaliplatin, 5FU, leucovorin/Irinotecan , 5FU, leucovorin,		Single-Institution Outcomes of Neoadjuvant Gemcitabine and Nab-Paclitaxel Combination in Borderline Resectable Pancreatic Adenocarcinoma: A Three-Year Retrospective Audit.	Cureus